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Discovery of LE phenomenon
The first autoantibody described in lupus was ‘Lupus 
factor’ by Hargraves at the Mayo Clinic in 1948. He 
reported the ‘LE phenomenon’ in bone marrow aspirates 
of patients with systemic lupus erythematosus (SLE). 
This finding is considered as hallmark in the field of 
SLE research. In 1950, Haserik from Cleveland Clinic 
induced the LE phenomenon in normal bone marrow cells 
incubated with serum from lupus patients. The study also 
demonstrated that the LE phenomenon was induced by 
the ‘anti-deoxyribonucleoprotein antibody’ present in the 
serum of lupus patients. In 1957, Holman and Kunkel 
found anti-nucleoprotein antibodies, which preceded full 
descriptions of antinuclear antibodies. In 1961, Anderson 
and co-workers reported a precipitation reaction against 
salivary gland extracts, induced by antibodies named SjD 
and SjT. In 1966, Eng Tan described the serum reaction 
against tissues extracts that contained ribonucleoproteins, 
particularly against Sm (Smith protein). Clark and Reichlin 
in 1969 characterized the Ro antigen. Alspaugh and 
Tan reported the existence of the SSA antigen, and the 
research group later demonstrated that Ro is antigenically 
identical to SSA. The ribonucleoprotein La or SSB was also 
detected at the same time. Ro52 was characterized in 1988.
These ribonucleoproteins serve as important biomarkers 
for autoimmune connective tissue diseases, especially for 
lupus and Sjögren’s syndrome. These autoantibodies are 
also of particular importance during pregnancy because 
they can induce neonatal pathologies.1
Physiological roles of Ro and 
La ribonucleoproteins
The Ro60 is a donut-shaped protein with binding sites for 
RNA. This ribonucleoprotein is localized in the nucleus 
and cytoplasm and its function depends on its location. 
Ro60 is associated with Y RNAs, and these small non-
coding RNAs may form complexes with Ro60, thereby 
preventing Ro60 from binding to misfolded ncRNAs. Study 
using Deinococcus radiodurans model has shown that an 
exonuclease polynucleotide phosphorylase (PNPase) 
is recruited to the Ro60-related Rsr/RNP complex. This 
recruitment induces conformational modification of the 
central cavity gateway of Ro60, which enables entry of a 
misfolded ncRNA for degradation.2, 3 In addition, Ro60 is 
likely involved in editing misfolded 5S rRNAs and in micro 
RNA (miRNA) regulation.4-6
Ro52, another member of the Ro family, is not related to 
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Ro60 because it is encoded by a different gene. It has a 
molecular weight of 54 kDa and belongs to the tripartite 
motif protein (TRIM) family (TRIM21).This molecule has 
a RING finger domain located at the N-terminal. Since 
the Ro52 domain displays E3-ligase activity, Ro52 can 
ubiquitinate different interferon (IFN) regulatory factors. 
Thus Ro52 participates in the regulation of cytokine 
production and the innate immune response. Moreover, 
literature evidence substantiates the role of anti-Ro52 
autoantibodies in inducing neonatal pathologies.7, 8
La or SSB autoantigen, a 48 kDa protein, functions as 
a transcription termination factor of RNA polymerase III. 
The ribonucleoprotein participates in the folding and 
maturation of RNA polymerase III transcripts and it also 
confers protection against exonuclease degradation. 
Additionally, the protein interacts with viral RNAs and plays 
a housekeeping role in the promotion of the global miRNA 
expression. Thus La binding to pre-miRNA is critical for 
stabilizing nascent pri-miRNA, and RNA binding occurs 
through the conserved La motif (LAM) and N-terminal 
RNA recognition motif (RRM1 and RRM2) domains.9 This 
ribonucleoprotein is important for cellular physiology and 
recent research has shown its relevance in human cancer 
transcriptomes and cancer prognosis.10
Anti-Ro and anti-La autoantibody 
pathological markers
Anti-Ro and anti-La autoantibodies are more prevalent 
in autoimmune connective tissue disease (CTD), and 
the range of associated diseases varies depending on 
the serotype ethnic group and/or the technology used for 
autoantibody detection.11 For example, anti-Ro is detected 
in 70-100% of patients with Sjögren’s syndrome, whereas 
La/SSB is detected in 40-90% of Sjögren’s patients.12 In 
SLE patients, the prevalence of anti-Ro is approximately 
68%,whereas anti-La prevalence is 23%. Notably, these 
autoantibodies are frequently detected as ‘antibody 
clusters’ in SLE and both anti-Ro/La autoantibodies are 
often associated with anti-DNA antibodies. Therefore, 
SLE patients displaying this autoantibody cluster, exhibit 
a clinical phenotype associated with increased kidney 
involvement, which is manifested by proteinuria and 
nephrotic syndrome. These patients may also have 
secondary Sjögren’s syndrome.13 In scleroderma and 
inflammatory myositis, anti-Ro prevalence is lower and 
ranges from 3-15%.12
Autoimmune diseases have been associated with 
detailed serotypes. For example, subacute cutaneous 
lupus erythematosus (SCLE) has been historically 
associated with anti-Ro60 or anti-La antibodies. The use 
of recombinant proteins, such as anti-Ro60 and anti-Ro52 
autoantibodies, has expanded the antigenic specificity of 
SCLE. Anti-Ro52 is an additional component of the SCLE 
autoantibody cluster.14-16 Therefore, the most objective 
methods for assessing certain autoantibodies as markers 
of disease should consider these autoantibody groups.
Apart from anti-Ro60, anti-Ro52, and anti-La antibodies, 
there is a wide range of other autoantibodies associated 
with systemic lupus erythematosus and Sjögren’s 
syndrome. The association of this autoantibody cluster with 
neonatal pathologies, induced by maternal autoantibodies, 
is discussed in the following sections.
Neonatal pathologies induced by anti-Ro and 
anti-La antibodies
Neonatal lupus (NL), with or without congenital heart block 
(CHB), is induced by maternal antinuclear antibodies 
(ANAs). Skin manifestations of neonatal lupus appear at 
birth or a few weeks later, and cutaneous lesions may persist 
for 16 weeks. CHB, another neonatal pathology associated 
with maternal ANAs, is characterized by intrauterine 
bradycardia or low heart rates at birth. It may persist for 
months, depending on the degree of the blockage. Both 
of these neonatal pathologies are associated with anti-Ro 
and/or anti-La antibodies.17-24
Molecular determinants of neonatal pathologies
The descriptions of neonatal clinical syndromes, induced 
by maternal antibodies, raise several questions: Why 
do anti-Ro and anti-La antibodies induce skin lesions 
in neonatal lupus? What determines the characteristic 
atrioventricular (AV) block in CHB? Which factors influence 
fibrosis of the AV node and determine permanent AV 
blocks?
Lee and co-workers have concluded that anti-Ro (SS-
A) antibodies may be directly involved in cutaneous 
disease. The study was conducted by transplanting 
the foreskin of newborn babies into nude mice and 
subsequently injecting with human anti-Ro antibodies. 
The mice developed erythematous lesions similar to those 
observed in neonatal lupus, and immune deposits of anti-
Ro antibodies occurred at dermoepidermal junctions and 
other skin structures. Additionally, the mice demonstrated 
that these antibodies produced antibody-dependent 
Internet Journal of Rheumatology and Clinical Immunology Page 2 of 6  Page 3 of 6
cytotoxicity.25 Subsequent studies have shown that the 
autoantibodies were found to produce apoptosis of basal 
keratinocytes, creating a major source of intracellular 
antigens, which induces the formation of local immune 
complexes, cytotoxicity, and production of inflammatory 
cytokines. These mechanisms appear to cause the skin 
lesions in neonatal lupus, but they generally disappear 
after the elimination of maternal antibodies.26
An autopsy study of infants, died due to congenital 
heart block (CHB), born to mothers with SLE, has 
shown fibrotic changes in the atrioventricular node. The 
study also reported that these changes affected early 
atrioventricular node development. Thus, nodal fibrosis 
presumably contributed to CHB.17 Buyon and co-workers 
have established the association of the CHB with maternal 
autoantibodies. They have also defined the autoimmune 
association of this neonatal pathology.
The research by Buyon and team has reported several 
clinical and experimental factors associated with the 
pathophysiology of congenital heart block.27-32 The current 
review highlights some of the important factors. Clinical 
observations have shown that the fetus may develop 
CHB between 22 and 26 weeks of pregnancy in mothers 
with anti-Ro and anti-La antibodies. This risk has been 
confirmed in several clinical studies and in experimental 
mouse models in which pregnant females are injected 
with anti-Ro60, anti-Ro52, and anti-La antibodies. The 
degree of AV block varies in 2-7% of animals and it is 
comparable to the incidence in humans.33-37
Chronic effects of maternal antibodies on fetal hearts 
have been observed during the prenatal care of women 
with lupus or Sjögren’s syndrome. Experimental studies 
conducted in animal models have demonstrated that 
induction of acute effects in animal models via anti-
Ro/La perfusion on denervated hearts (Langendorff-
perfused hearts) caused bradycardia.35, 38-41 However, 
none of the clinical and experimental findings clarifies the 
underlying cause of bradycardia. The AV node is crucial 
for the genesis and propagation of the electric impulse 
into ventricles. Therefore, electropropagation is dependent 
on L-type calcium channels, and experimental evidence 
indicates that the CHB-IgG functionally inhibits L-type 
calcium channels and induces abnormalities in electrical 
conduction of the cardiac myocytes. These abnormalities 
include sinus bradycardia, prolonged PR, and complete AV 
block.42-46
L-type calcium channels and congenital 
heart block
The calcium influx through calcium channels (CaV) in cardiac 
muscles generates multifunctional signals in excitable 
cells that trigger cardiac contraction. CaV also controls the 
duration of action potential and regulates gene expression. 
These voltage-gated calcium channels consist of at least 
four subunits; the α1 subunit forms the pore structure and 
contains four homologous domains, and each domain 
encompasses six membrane spanning segments that are 
connected by several intracellular loops. Each domain has 
a voltage sensor. Additionally, accessory subunits such as 
α2δ and β and γ are implicated in anchorage, trafficking, 
and regulatory functions. 
Different CACNA1 genes encode ten α subunits of the 
CaV1 channel. The CaV1.2 α1 gene contains 50 exons 
that display at least 13 alternative splicing loci, resulting 
in protein diversity. Therefore, during development, CaV1.2 
α1 expression changes due to splice variants. These 
variants are associated with a depolarizing shift activation, 
suggesting a possible maturation role in fetal and mature 
isoforms of juvenile cardiomyocytes.47, 48 Adult ventricular 
myocytes only express the CaV1.2 α1C subunit.
49
CHB-IgG selectively inhibits the currents generated by 
L-type and T-type calcium channels in freshly isolated 
myocytes from the AV node. However, because α1C in the 
L-channel plays a minimal role in diastolic depolarization, 
the α1D isoform has emerged as an important component 
of the pacemaker node. This isoform is also expressed 
in neuroendocrine tissue. In contrast, the expression of 
α1D is distinct in the sinoatrial node. Therefore, these 
channels play an important role in inducing AV block and 
causing sinusal bradycardia in CHB. Brucato et al. have 
reported a few cases of infants with sinus bradycardia 
associated with anti-Ro maternal antibodies.50 The in vitro 
studies conducted using the sera from babies with CHB 
had demonstrated that anti-Ro inhibited α1D and α1C 
channel activity, suggesting that the effect of anti-Ro may 
functionally affect the AV node and/or sinoatrial node (Fig. 
1).41, 51
Although clinical and experimental evidence suggests 
that anti-Ro and anti-La antibodies induce congenital 
heart block, it is unclear how these maternal antibodies 
interact with their intracellular molecular targets in the 
fetal heart. Miranda-Carus and colleagues demonstrated 
that Ro and La ribonucleoproteins translocate to the 
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cell membrane of apoptotic cardiomyocytes.52 Further, 
exposure to these proteins on the cell surface, in the 
presence of maternal antibodies, induces the formation of 
immune complexes, which are subsequently cleared by 
scavengers. The immune complexes stimulate signaling 
pathways in infiltrating macrophages, causing excess 
cytokine production including TGFβ. This in turn induces 
the transdifferentiation of cardiomyocytes into fibroblasts, 
ultimately producing fibrosis in the AV node.53
The α1D and α1C channels are functionally inhibited by 
maternal autoantibodies in CHB. However, the underlying 
mechanism remains unknown. The experiments conducted 
by Boutjdir et. al and other researchers have demonstrated 
that anti-Ro and anti-La autoantibodies cross-react 
with antigens from the pore-forming subunit of α1C and 
α1D channels. Additionally, a fraction of these maternal 
antibodies recognizes GST fusion proteins that express 
the extracellular S5-S6 loop of the first domain of the α1D 
subunit of L-type calcium and the α1G subunit of T-type 
calcium channels.54, 55
Conclusion
It has been 38 years and 25 years respectively, after 
reporting the first clinical description of CHB and its 
association with maternal anti-Ro and anti-La antibodies. 
The pathophysiology of CHB has been clarified by a large 
group of clinical and basic scientists at the cellular and 
molecular levels. Further research elucidating the role of 
autoantigen-autoantibody system may assist in developing 
newer strategies for treating autoimmune diseases.
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